Europe's new paediatric rules bear fruit
This article was originally published in Scrip
Executive Summary
The EU's drive to encourage the development of drugs for children has finally borne fruit in the form of a paediatric version of Merck Sharp & Dohme's Cancidas for use in fungal infections. This is a small, but very welcome, first step towards ensuring that children have a full range of medicines at their disposal and are not treated like "small adults".